These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38951434)

  • 1. Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b.
    Shimoda K; Qin A; Komatsu N; Kirito K
    Int J Hematol; 2024 Aug; 120(2):151-156. PubMed ID: 38951434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
    Illés Á; Pinczés LI; Egyed M
    Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):3-7. PubMed ID: 33118413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
    Qin A; Wu D; Li Y; Zhang J; Wang W; Shen W; Liao J; Lin S; Chang C; Chen H; Cui J; Su X
    Br J Clin Pharmacol; 2024 Jun; 90(6):1493-1502. PubMed ID: 38500445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
    Barbui T; Vannucchi AM; De Stefano V; Masciulli A; Carobbio A; Ferrari A; Ghirardi A; Rossi E; Ciceri F; Bonifacio M; Iurlo A; Palandri F; Benevolo G; Pane F; Ricco A; Carli G; Caramella M; Rapezzi D; Musolino C; Siragusa S; Rumi E; Patriarca A; Cascavilla N; Mora B; Cacciola E; Mannarelli C; Loscocco GG; Guglielmelli P; Betti S; Lunghi F; Scaffidi L; Bucelli C; Vianelli N; Bellini M; Finazzi MC; Tognoni G; Rambaldi A
    Lancet Haematol; 2021 Mar; 8(3):e175-e184. PubMed ID: 33476571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
    Edahiro Y; Ohishi K; Gotoh A; Takenaka K; Shibayama H; Shimizu T; Usuki K; Shimoda K; Ito M; VanWart SA; Zagrijtschuk O; Qin A; Kawase H; Miyachi N; Sato T; Komatsu N; Kirito K
    Int J Hematol; 2022 Aug; 116(2):215-227. PubMed ID: 35430707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
    Gisslinger H; Klade C; Georgiev P; Krochmalczyk D; Gercheva-Kyuchukova L; Egyed M; Rossiev V; Dulicek P; Illes A; Pylypenko H; Sivcheva L; Mayer J; Yablokova V; Krejcy K; Grohmann-Izay B; Hasselbalch HC; Kralovics R; Kiladjian JJ;
    Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.
    Wagner SM; Melchardt T; Greil R
    Drugs Today (Barc); 2020 Mar; 56(3):195-202. PubMed ID: 32282866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
    Kiladjian JJ; Marin FF; Al-Ali HK; Alvarez-Larrán A; Beggiato E; Bieniaszewska M; Breccia M; Buxhofer-Ausch V; Cerna O; Crisan AM; Danaila CD; De Stefano V; Döhner K; Empson V; Gora-Tybor J; Griesshammer M; Grosicki S; Guglielmelli P; García-Gutierrez V; Heidel FH; Illés A; Tomuleasa C; James C; Koschmieder S; Krauth MT; Krejcy K; Lazaroiu MC; Mayer J; Nagy ZG; Nicolini FE; Palandri F; Pappa V; Reiter AJ; Sacha T; Schlager S; Schmidt S; Terpos E; Unger M; Wölfler A; Cirici BX; Klade C
    Ann Hematol; 2024 Jul; 103(7):2299-2310. PubMed ID: 38438627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.
    Miyachi N; Zagrijtschuk O; Kang L; Yonezu K; Qin A
    Clin Drug Investig; 2021 Apr; 41(4):391-404. PubMed ID: 33725322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
    Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment.
    Qin A
    Clin Ther; 2024 May; 46(5):439-440. PubMed ID: 38697872
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera.
    Gerds AT; Castro C; Snopek F; Flynn MM; Ellis AG; Manning M; Urbanski R
    J Comp Eff Res; 2023 Sep; 12(9):e230066. PubMed ID: 37531245
    [No Abstract]   [Full Text] [Related]  

  • 13. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.
    Verger E; Soret-Dulphy J; Maslah N; Roy L; Rey J; Ghrieb Z; Kralovics R; Gisslinger H; Grohmann-Izay B; Klade C; Chomienne C; Giraudier S; Cassinat B; Kiladjian JJ
    Blood Cancer J; 2018 Oct; 8(10):94. PubMed ID: 30287855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
    Gisslinger H; Zagrijtschuk O; Buxhofer-Ausch V; Thaler J; Schloegl E; Gastl GA; Wolf D; Kralovics R; Gisslinger B; Strecker K; Egle A; Melchardt T; Burgstaller S; Willenbacher E; Schalling M; Them NC; Kadlecova P; Klade C; Greil R
    Blood; 2015 Oct; 126(15):1762-9. PubMed ID: 26261238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
    Jin J; Qin A; Zhang L; Shen W; Wang W; Zhang J; Li Y; Wu D; Xiao Z
    Future Oncol; 2023 Apr; 19(11):753-761. PubMed ID: 37129584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment.
    Suo SS; Fu RF; Qin A; Shao ZH; Bai J; Chen SN; Duan MH; Zhou H; Xu N; Zhang SJ; Zuo XL; Du X; Wang L; Li P; Zhang XH; Wu DX; Li YN; Zhang JJ; Wang W; Shen WH; Zagrijtschuk O; Sato T; Xiao ZJ; Jin J
    J Hematol; 2024 Apr; 13(1-2):12-22. PubMed ID: 38644985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms- Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience.
    Popova-Labachevska M; Cvetanoski M; Ridova N; Trajkova S; Stojanovska-Jakimovska S; Mojsovska T; Stojanoski Z; Pivkova-Veljanovska A; Panovska-Stavridis I
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2023 Dec; 44(3):57-62. PubMed ID: 38109450
    [No Abstract]   [Full Text] [Related]  

  • 18. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
    Quintás-Cardama A; Kantarjian H; Manshouri T; Luthra R; Estrov Z; Pierce S; Richie MA; Borthakur G; Konopleva M; Cortes J; Verstovsek S
    J Clin Oncol; 2009 Nov; 27(32):5418-24. PubMed ID: 19826111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.
    Jin J; Zhang L; Qin A; Wu D; Shao Z; Bai J; Chen S; Duan M; Zhou H; Xu N; Zhang S; Zuo X; Du X; Wang L; Li P; Zhang X; Li Y; Zhang J; Wang W; Shen W; Zagrijtschuk O; Urbanski R; Sato T; Xiao Z
    Exp Hematol Oncol; 2023 Jun; 12(1):55. PubMed ID: 37344895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.
    Them NC; Bagienski K; Berg T; Gisslinger B; Schalling M; Chen D; Buxhofer-Ausch V; Thaler J; Schloegl E; Gastl GA; Wolf D; Strecker K; Egle A; Melchardt T; Burgstaller S; Willenbacher E; Zagrijtschuk O; Klade C; Greil R; Gisslinger H; Kralovics R
    Am J Hematol; 2015 Apr; 90(4):288-94. PubMed ID: 25545244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.